--- title: "The Hong Kong Market's \"Leftover\" Bin: Who's Faking It and Who's Real?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296333763.md" description: "We dig into a chaotic mix of Hong Kong’s niche stocks, ranging from fertility clinics and biotech CDMOs to inverse ETFs. While some boast real revenue and strategic backing, others look like pure noise. Here's a sharp look at who actually matters." datetime: "2026-08-19T09:44:34.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296333763.md) - [en](https://longbridge.com/en/news/296333763.md) - [zh-HK](https://longbridge.com/zh-HK/news/296333763.md) generator: "portal-rs" --- # The Hong Kong Market's "Leftover" Bin: Who's Faking It and Who's Real? There is a neglected corner of the Hong Kong market where companies that completely defy the standard "Big Tech" narratives are dumped. We are talking about an erratic mix of fertility clinics, manhole cover manufacturers, and double-inverse Tesla trackers. While most analysts ignore this space, it is actually the perfect place to see what the market truly values when the hype is stripped away. Some of these players are quietly building moats, while others are essentially sleepwalking. This is wild, and here's why. Let's start with the massive divide in the healthcare and biotech group. **Jinyi Group (1951.HK)** is aggressively trying to play the cross-border game by operating assisted reproductive services (ARS) from Chengdu all the way to Southern California. Offering everything from IVF to psychological counseling sounds comprehensive, but maintaining a foothold in the highly saturated US West Coast market takes more than a glossy expansion plan. On the flip side, **BioDlink (1875.HK)** is executing a much more realistic playbook. Wuxi XDC acquired a 60% stake in the CDMO player in 2026, officially plugging it into a world-class manufacturing platform. When you can leverage ADC technology and simultaneously sell commercialized anti-tumor drugs, securing the "Emerging CDMO of the Year" award actually means something. For **Tennor Therapeutics (6872.HK)**, the long-term value of its differentiated disease therapies remains to be proven by hard clinical data. Meanwhile, household medical device maker **Cofoe Medical (1187.HK)** suffered a rather embarrassing Hong Kong debut in May 2026. Despite raising roughly HKD 1 billion in its offering, the stock slumped nearly 6% on its first day. The market's patience is thin—investors simply won't blindly underwrite low-barrier medical hardware without a compelling tech advantage. Then we have the tech hardware and materials divergence. **SUNMI (6810.HK)** is easily the standout of this entire bunch. Its shares skyrocketed more than threefold on its April 2026 debut after pulling off a ridiculous 2,000x oversubscription. Why the frenzy? Because its proprietary SUNMI OS is fundamentally digitizing offline retail, making it a legitimate business IoT (BIoT) powerhouse rather than just another terminal manufacturer. Compare that to **Shandong Baogai (8090.HK)**, which had a completely flat opening in July 2026. At the end of the day, producing composite manhole covers and resin drainage trenches is deeply tethered to grueling infrastructure cycles. Good luck spinning a sexy growth narrative out of that. The financial services and pure trading instruments are equally polarized. **DL Holdings (1709.HK)** is making a clear push to lock down Asia's high-net-worth capital, snapping up the remaining 55% of its family office arm at a HKD 500 million valuation. It's a solid strategy. But look at life insurance intermediary **Shouhui Industrial Financial (2621.HK)**—its revenue dropped 15% in 2024, and it tanked over 14% on its IPO day in May 2025. Why aren't you moving faster? Traditional brokerages are getting utterly crushed by digital distribution, and tweaking the edges won't save them. Finally, we have the pure market tools. The **CSOP Tesla Daily (-2x) Inverse Product (7366.HK)** is tailor-made for those who want to gamble on Elon's next controversial tweet. For everyone else looking for actual safety, the **Global X US Treasury 3-5 Year ETF (3450.HK)** is the designated parking spot. With a net asset value topping HKD 374 million, it clearly shows where the smart, risk-averse money is hiding. Good luck to the thrill-seekers. *This article does not constitute investment advice.* ### Related Stocks - [01951.HK](https://longbridge.com/en/quote/01951.HK.md) - [01875.HK](https://longbridge.com/en/quote/01875.HK.md) - [06872.HK](https://longbridge.com/en/quote/06872.HK.md) - [01187.HK](https://longbridge.com/en/quote/01187.HK.md) - [06810.HK](https://longbridge.com/en/quote/06810.HK.md) - [08090.HK](https://longbridge.com/en/quote/08090.HK.md) - [01709.HK](https://longbridge.com/en/quote/01709.HK.md) - [02621.HK](https://longbridge.com/en/quote/02621.HK.md) ## Related News & Research - [Jinxin Fertility Signals Sharp Profit Turnaround on Recovery in Core Markets](https://longbridge.com/en/news/293373330.md) - [Jinxin Fertility says H1 NPVs rise 9.1% to 24,169](https://longbridge.com/en/news/293357812.md) - [Jinxin Fertility Posts Solid Growth in Fertility and Obstetrics Services for H1 2026](https://longbridge.com/en/news/293362622.md) - [Sunmi controlling shareholder Lin Zhe holds 24.49% stake, 76.43% voting rights](https://longbridge.com/en/news/295244658.md) - [07:35 ETSUNMI erweitert SoftPOS-Plattform, um sichere kontaktlose Zahlungen auf weitere intelligente Geschäftsgeräte zu bringen](https://longbridge.com/en/news/293608772.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**